Share on facebook
Share on twitter

Missouri Senate Disappoints Pro-Lifers on MOSIRA

Missouri Right to Life

Press Release

For Immediate Release
September 14, 2011

For Information

The following statement can be attributed to Pam Fichter, President of Missouri Right to Life:

Today the Missouri Senate disappointed pro-life citizens across the state when it third read and passed the Missouri Science Innovation & Reinvestment Act (MOSIRA) without adequate pro-life protections.

While an amendment containing protective language was introduced Tuesday evening, in a carefully choreographed maneuver, Senators replaced this amendment with another amendment that required only an additional, ineffective reporting requirement.

Missouri Right to Life had urged the Senate to include the following language, which would provide clear prohibitions against unethical research: Public funds shall not be expended, paid, or granted to or on behalf of an existing or proposed research project that involves abortion services, human cloning, or prohibited human research as defined in section 196.1127.

Instead, the Senate approved language that required Missouri Technology Corporation (MTC) to announce and post on-line the proposed recipients of public funds they would control ten days prior to distribution of those funds.  The language would have no prohibitive effect on unethical research.

MOSIRA also includes language that requires the recipient organizations to report on the specific research they perform with the public moneys they receive from the MTC.  However, this reporting would be self-monitored with no official oversight and rely on the faulty definition of human cloning now in the Missouri constitution as a result of Amendment 2.

As this legislation will now go to the Missouri House of Representatives, Missouri Right to Life urges pro-life Representatives in the House to amend MOSIRA with true pro-life protections provided in the language above.

Scroll to Top

This website uses cookies to ensure you get the best experience on our website.